These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 37637734)

  • 1. Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir.
    Hu Y; Lewandowski EM; Tan H; Zhang X; Morgan RT; Zhang X; Jacobs LMC; Butler SG; Gongora MV; Choy J; Deng X; Chen Y; Wang J
    ACS Cent Sci; 2023 Aug; 9(8):1658-1669. PubMed ID: 37637734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir.
    Hu Y; Lewandowski EM; Tan H; Zhang X; Morgan RT; Zhang X; Jacobs LMC; Butler SG; Gongora MV; Choy J; Deng X; Chen Y; Wang J
    bioRxiv; 2022 Sep; ():. PubMed ID: 36119652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hotspot residues and resistance mutations in the nirmatrelvir-binding site of SARS-CoV-2 main protease: Design, identification, and correlation with globally circulating viral genomes.
    Padhi AK; Tripathi T
    Biochem Biophys Res Commun; 2022 Nov; 629():54-60. PubMed ID: 36113178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Inhibition Potency of Nirmatrelvir against Main Protease Mutants of SARS-CoV-2 Variants.
    Jiang H; Zhou Y; Zou X; Hu X; Wang J; Zeng P; Li W; Zeng X; Zhang J; Li J
    Biochemistry; 2023 Jul; 62(13):2055-2064. PubMed ID: 37222536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors.
    Tan B; Sacco M; Tan H; Li K; Joyce R; Zhang X; Chen Y; Wang J
    Eur J Med Chem; 2023 Nov; 259():115667. PubMed ID: 37482021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 3CL
    Heilmann E; Costacurta F; Moghadasi SA; Ye C; Pavan M; Bassani D; Volland A; Ascher C; Weiss AKH; Bante D; Harris RS; Moro S; Rupp B; Martinez-Sobrido L; von Laer D
    Sci Transl Med; 2023 Jan; 15(678):eabq7360. PubMed ID: 36194133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive study of SARS-CoV-2 main protease (M
    Costacurta F; Dodaro A; Bante D; Schöppe H; Sprenger B; Moghadasi SA; Fleischmann J; Pavan M; Bassani D; Menin S; Rauch S; Krismer L; Sauerwein A; Heberle A; Rabensteiner T; Ho J; Harris RS; Stefan E; Schneider R; Kaserer T; Moro S; von Laer D; Heilmann E
    bioRxiv; 2023 Oct; ():. PubMed ID: 37808638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Large scale analysis of the SARS-CoV-2 main protease reveals marginal presence of nirmatrelvir-resistant SARS-CoV-2 Omicron mutants in Ontario, Canada, December 2021-September 2023.
    Duvvuri V; Shire F; Isabel S; Braukmann T; Clark S; Marchand-Austin A; Eshaghi A; Bandukwala H; Varghese N; Li Y; Sivaraman K; Hussain H; Cronin K; Sullivan A; Li A; Zygmunt A; Ramotar K; Kus J; Hasso M; Corbeil A; Gubbay J; Patel S
    Can Commun Dis Rep; 2024 Oct; 50(10):365-374. PubMed ID: 39386278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A yeast-based system to study SARS-CoV-2 M
    Ou J; Lewandowski EM; Hu Y; Lipinski AA; Morgan RT; Jacobs LMC; Zhang X; Bikowitz MJ; Langlais P; Tan H; Wang J; Chen Y; Choy JS
    bioRxiv; 2022 Aug; ():. PubMed ID: 35982672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease.
    Noske GD; de Souza Silva E; de Godoy MO; Dolci I; Fernandes RS; Guido RVC; Sjö P; Oliva G; Godoy AS
    J Biol Chem; 2023 Mar; 299(3):103004. PubMed ID: 36775130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Nirmatrelvir Resistance Mutations in SARS-CoV-2 3CLpro: A Computational-Experimental Approach.
    Havranek B; Demissie R; Lee H; Lan S; Zhang H; Sarafianos S; Ayitou AJ; Islam SM
    J Chem Inf Model; 2023 Nov; 63(22):7180-7188. PubMed ID: 37947496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distal Protein-Protein Interactions Contribute to SARS-CoV-2 Main Protease Substrate Binding and Nirmatrelvir Resistance.
    Lewandowski EM; Zhang X; Tan H; Jaskolka-Brown A; Kohaal N; Frazier A; Madsen JJ; Jacobs LMC; Wang J; Chen Y
    bioRxiv; 2024 Apr; ():. PubMed ID: 38617221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir.
    Yang KS; Leeuwon SZ; Xu S; Liu WR
    J Med Chem; 2022 Jul; 65(13):8686-8698. PubMed ID: 35731933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of SARS-CoV-2 Mutations after Nirmatrelvir Treatment in a Lung Cancer Xenograft Mouse Model.
    Kang BM; Kim D; Kim J; Baek K; Park S; Shin HE; Lee MH; Kim M; Kim S; Lee Y; Kwon HJ
    Biomol Ther (Seoul); 2024 Jul; 32(4):481-491. PubMed ID: 38835145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly specific SARS-CoV-2 main protease (M
    Rauch S; Costacurta F; Schöppe H; Peng JY; Bante D; Erisoez EE; Sprenger B; He X; Moghadasi SA; Krismer L; Sauerwein A; Heberle A; Rabensteiner T; Wang D; Naschberger A; Dunzendorfer-Matt T; Kaserer T; von Laer D; Heilmann E
    Antiviral Res; 2024 Nov; 231():105969. PubMed ID: 39053514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive Mutation in the Main Protease Cleavage Site of Feline Coronavirus Renders the Virus More Resistant to Main Protease Inhibitors.
    Jiao Z; Yan Y; Chen Y; Wang G; Wang X; Li L; Yang M; Hu X; Guo Y; Shi Y; Peng G
    J Virol; 2022 Sep; 96(17):e0090722. PubMed ID: 36000844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.
    Iketani S; Mohri H; Culbertson B; Hong SJ; Duan Y; Luck MI; Annavajhala MK; Guo Y; Sheng Z; Uhlemann AC; Goff SP; Sabo Y; Yang H; Chavez A; Ho DD
    bioRxiv; 2022 Aug; ():. PubMed ID: 36032976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.
    Iketani S; Mohri H; Culbertson B; Hong SJ; Duan Y; Luck MI; Annavajhala MK; Guo Y; Sheng Z; Uhlemann AC; Goff SP; Sabo Y; Yang H; Chavez A; Ho DD
    Nature; 2023 Jan; 613(7944):558-564. PubMed ID: 36351451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir.
    Ullrich S; Ekanayake KB; Otting G; Nitsche C
    Bioorg Med Chem Lett; 2022 Apr; 62():128629. PubMed ID: 35182772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.